Somatostatin infusion increases intestinal ischemia and does not improve vasoconstrictor response to norepinephrine in ovine endotoxemia

Shock

Volumn 30, Issue 5, 2008, Pages 603-609

  Lauer, Stefan ^a   Daudel, Fritz ^a,d   Traber, Daniel L ^b   Noter, Jerzy Roch ^a   Ertmer, Christian ^a   Morelli, Andrea ^c   Van Aken, Hugo ^a   Lange, Matthias ^a   Rehberg, Sebastian ^a   Ellger, Björn ^a   Stubbe, Henning D ^a   Kruse, Claudius ^a   Bone, Hans Georg ^a   Westphal, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Endotoxemia; Hemodynamics; Norepinephrine; Oxygen transport; Sepsis; Sheep; Somatostatin

Indexed keywords

ENDOTOXIN; NITRATE; NITRITE; NORADRENALIN; SOMATOSTATIN;

ACID BASE BALANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONTINUOUS INFUSION; CONTROLLED STUDY; ENDOTOXEMIA; FEMALE; HEART INDEX; HEART RATE; HYPOTENSION; INFLAMMATION; INTESTINE ISCHEMIA; LACTATE BLOOD LEVEL; LOADING DRUG DOSE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN TRANSPORT; PRESSOR RESPONSE; SEPTIC SHOCK; SHEEP; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC VASCULAR RESISTANCE; TACHYPHYLAXIS; VASOCONSTRICTION;

ANIMALS; ENDOTOXEMIA; FEMALE; HEMODYNAMICS; HYPOTENSION; ISCHEMIA; NITRATES; NITRITES; NOREPINEPHRINE; OXYGEN CONSUMPTION; SHEEP; SOMATOSTATIN; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS;

EID: 55949096783     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31816f1bb2     Document Type: Article

References (38)

1. Morrison DC, Ryan JL: Endotoxins and disease mechanisms. Annu Rev Med 38:417-432, 1987.
2. Briard N, Guillaume V, Frachebois C, Rico-Gomez M, Sauze N, Oliver C, Dutour A: Endotoxin injection increases growth hormone and somatostatin secretion in sheep. Endocrinology 139:2662-2669, 1998.
3. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345:588-595, 2001.
4. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227-242, 1990.
5. Meyer J, Booke M, Waurick R, Prien T, Van Aken H: Nitric oxide synthase inhibition restores vasopressor effects of norepinephrine in ovine hyperdynamic sepsis. Anesth Analg 83:1009-1013, 1996.
6. Meadows D, Edwards JD, Wilkins RG, Nightingale P: Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 16:663-666, 1988.
7. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE: Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 32: S455-S465, 2004.
8. Imura H, Fukata J: Endocrine-paracrine interaction in communication between the immune and endocrine systems. Activation of the hypothalamic- pituitary-adrenal axis in inflammation. Eur J Endocrinol 130:32-37, 1994.
9. Dadoun F, Guillaume V, Sauze N, Farisse J, Velut JG, Orsoni JC, Gaillard R, Oliver C: Effect of endotoxin on the hypothalamic-pituitary-adrenal axis in sheep. Eur J Endocrinol 138:193-197, 1998.
10. Makara GB, Stark E, Meszaros T: Corticotrophin release induced by E. coli endotoxin after removal of the medial hypothalamus. Endocrinology 88: 412-414, 1971.
11. Rivier C, Chizzonite R, Vale W: In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1. Endocrinology 125:2800-2805, 1989.
12. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341:785-792, 1999.
13. Tyden G, Samnegard H, Thulin L, Muhrbeck O, Efendic S: Circulatory effects of somatostatin in anesthetized man. Acta Chir Scand 145:443-446, 1979.
14. Cirera I, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, Bosch J, Rodes J: Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology 22:106-111, 1995.
15. Villanueva C, Planella M, Aracil C, Lopez-Balaguer JM, Gonzalez B, Minana J, Balanzo J: Hemodynamic effects of terlipressin and high somatostatin dose during acute variceal bleeding in nonresponders to the usual somatostatin dose. Am J Gastroenterol 100:624-630, 2005.
16. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, et al.: Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29:1690-1697, 1999.
17. Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, Bone HG, Van Aken H, Traber DL, Westphal M: Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 28:623-629, 2007.
18. Lange M, Szabo C, Van Aken H, Williams W, Traber DL, Daudel F, Broking K, Salzman AL, Bone HG, Westphal M: Short-term effects of glipizide (an adenosine triphosphate-sensitive potassium channel inhibitor) on cardiopulmonary hemodynamics and global oxygen transport in healthy and endotoxemic sheep. Shock 26:516-521, 2006.
19. Stubbe HD, Traber DL, Booke M, Traber LD, Westphal M, Van Aken H, Hinder F: Role of atrial natriuretic peptide in pulmonary permeability and vasoregulation in ovine sepsis. Crit Care Med 32:2491-2495, 2004.
20. Westphal M, Stubbe H, Sielenkamper AW, Ball C, Van Aken H, Borgulya R, Bone HG: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 31: 1502-1508, 2003.
21. Westphal M, Stubbe H, Bone HG, Daudel F, Vocke S, Van Aken H, Booke M: Hemodynamic effects of exogenous adrenomedullin in healthy and endotoxemic sheep. Biochem Biophys Res Commun 296:134-138, 2002.
22. Westphal M, Stubbe H, Sielenkamper AW, Borgulya R, Van Aken H, Ball C, Bone HG: Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 29:301-308, 2003.
23. Westphal M, Sielenkamper AW, Van Aken H, Stubbe HD, Daudel F, Schepers R, Schulte S, Bone HG: Dopexamine reverses the vasopressin-associated impairment in tissue oxygen supply but decreases systemic blood pressure in ovine endotoxemia. Anesth Analg 99:878-885, table of contents, 2004.
24. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN: Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 101:478-483, 1970.
25. Haglund U, Hulten L, Ahren C, Lundgren O: Mucosal lesions in the human small intestine in shock. Gut 16:979-984, 1975.
26. Traber DL: Animal models: the sheep. Crit Care Med 28:591-592, 2000.
27. Vincent JL: Hemodynamic support in septic shock. Intensive Care Med 27:S80-S92, 2001.
28. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 20: 157-198, 1999.
29. Scarpignato C, Pelosini I: Somatostatin for upper gastrointestinal hemorrhage and pancreatic surgery. A review of its pharmacology and safety. Digestion 60:1-16, 1999.
30. Wiest R, Tsai MH, Groszmann RJ: Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats. Gastroenterology 120:975-983, 2001.
31. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 259:H1038-H1043, 1990.
32. Bode-Boger SM, Boger RH, Loffler M, Tsikas D, Brabant G, Frolich JC: L-Arginine stimulates NO-dependent vasodilation in healthy humans - effect of somatostatin pretreatment. J Investig Med 47:43-50, 1999.
33. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M: Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med 203:563-571, 2006.
34. Landa JI, Alvarez Sanchez J, Grau M, Sanchez JA, Balibrea JL: Somatostatin reduces the levels of tumor necrosis factor alpha in a rat model of endotoxemia induced by lipopolysaccharide. Res Exp Med (Berl) 195:317-325, 1995.
35. Pawlik WW, Gustaw P, Czarnobilski K, Sendur R, Konturek SJ: Effects of somatostatin on intestinal circulation and oxygen consumption. Acta Physiol Hung 74:277-283, 1989.
36. Reichlin S: Somatostatin. N Engl J Med 309:1495-1501, 1983.
37. Moreau R, Lebrec D: The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 43:385-394, 2006.
38. Westphal M, Freise H, Kehrel BE, Bone HG, Van Aken H, Sielenkamper AW: Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 32:194-200, 2004.